pharma · Migraine · Narcolepsy
H. Lundbeck A/S
H. Lundbeck A/S is a pharma organization headquartered in Valby, CN. Primary therapeutic focus areas include Migraine, Narcolepsy, Schizophrenia, Multiple System Atrophy, Chronic Migrane, Migrane, Medication Overuse Head
Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN HQ
112 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN
- Employees
- 112
- Programs
- 17
- Drugs
- 14
- Patents
- 0
Lu AF35700
Phase 3 · small molecule · Treatment-resistant Schizophrenia
Lu AF35700 for Treatment-resistant Schizophrenia is a Phase 3 program (small_molecule) at H. Lundbeck A/S with 1 ClinicalTrials.gov record(s).
Internal code 17303A
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- H. Lundbeck A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Treatment-resistant Schizophrenia
- Status
- terminated
- Trials
- 1